MEDS

TRxADE HEALTH, Inc. [MEDS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MEDS Stock Summary

Top 10 Correlated ETFs

MEDS


Top 10 Correlated Stocks

MEDS


In the News

08:14 29 Mar 2024 MEDS

Why Is Trxade Health (MEDS) Stock Up 230% Today?

Trxade Health (NASDAQ: MEDS ) stock is soaring higher on Tuesday after the U.S. health services IT company announced a major asset sale. According to a filing with the Securities and Exchange Commission (SEC), wholly-owned subsidiary Trxade, Inc. is going to sell virtually all of its assets to Micro Merchant Systems.

04:15 29 Mar 2024 MEDS

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the second quarter 2023, after market close on August 14, 2023.

09:11 29 Mar 2024 MEDS

Why Is Trxade Health (MEDS) Stock Down 13% Today?

Trxade Health (NASDAQ: MEDS ) stock is falling on Tuesday after the company announced it would undergo a merger with Superlatus . That merger will see Trxade Health distribute 3,839,176 shares of MEDS stock to current shareholders in Superlatus.

01:27 29 Mar 2024 MEDS

TRxADE Health (MEDS) Stock Soars 60% on Reverse Split

One of the biggest movers in today's market is little-known health tech company TRxADE Health (NASDAQ: MEDS ). Shares of MEDS stock have rocketed more than 60% higher as of this writing on an otherwise uneventful day in the market.

10:30 29 Mar 2024 MEDS

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Prashant Patel - Interim Chief Financial Officer Suren Ajjarapu - Founder, Chairman and Chief Executive Officer Conference Call Participants Allen Klee - Maxim Group LLC Howard Halpern - Taglich Brothers, LLC Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

07:45 29 Mar 2024 MEDS

TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates

TRxADE (MEDS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.12 per share a year ago.

04:15 29 Mar 2024 MEDS

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

TAMPA, FL / ACCESSWIRE / May 5, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023.

12:20 29 Mar 2024 MEDS

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

TAMPA, FL / ACCESSWIRE / April 25, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 8, 2023.

09:30 29 Mar 2024 MEDS

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q4 2022 Earnings Conference Call March 27, 2023 5:30 PM ET Company Participants Prashant Patel - CFO Surendra Ajjarapu - Founder, Chairman and CEO Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

07:47 29 Mar 2024 MEDS

TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates

TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MEDS Financial details

Company Rating
Neutral
Market Cap
29M
Income
-7.33M
Revenue
9.09M
Book val./share
4.89
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-0.79
Forward P/E
-
PEG
-0.01
P/S
0.66
P/B
-2.62
P/C
1017
P/FCF
-23.9
Quick Ratio
0.36
Current Ratio
0.49
Debt / Equity
0.56
LT Debt / Equity
0.09
-
-
EPS (TTM)
-4.61
EPS next Y
-
EPS next Q
-0.15
EPS this Y
-0%
EPS next Y
-
EPS next 5Y
-90.23%
EPS last 5Y
NAN%
Revenue last 5Y
24.47%
Revenue Q/Q
-8.58%
EPS Q/Q
-48.62%
-
-
-
-
SMA20
66.67%
SMA50
200%
SMA100
150%
Inst Own
0.05%
Inst Trans
0.02%
ROA
-115%
ROE
-1132%
ROC
2.66%
Gross Margin
65%
Oper. Margin
-15%
Profit Margin
-46%
Payout
-
Shs Outstand
1.21M
Shs Float
848.8K
-
-
-
-
Target Price
-
52W Range
3.69-44.56
52W High
-76.89%
52W Low
+239%
RSI
43
Rel Volume
0.25
Avg Volume
435.48K
Volume
109.2K
Perf Week
-49.25%
Perf Month
127.01%
Perf Quarter
52.93%
Perf Half Y
44.67%
-
-
-
-
Beta
1.902
-
-
Volatility
6.02%, 8.56%
Prev Close
6.49%
Price
10.17
Change
8.77%

MEDS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.661.252.221.221.35
Net income per share
0-0.07-0.33-0.51-0.51
Operating cash flow per share
0.050.02-0.29-0.32-0.18
Free cash flow per share
0.040.01-0.29-0.32-0.23
Cash per share
0.150.480.770.380.13
Book value per share
0.150.71.130.460.09
Tangible book value per share
0.020.581.130.46-0.01
Share holders equity per share
0.150.71.130.460.09
Interest debt per share
0.150.180.090.160.23
Market cap
26.21M97.83M611.44M288.04M51.26M
Enterprise value
26.19M95.96M606.15M286.17M51.71M
P/E ratio
2.9K-238.77-238.34-70.03-11.89
Price to sales ratio
6.8413.1635.7129.134.48
POCF ratio
95.89690.04-276.07-112.24-33.59
PFCF ratio
101.451.64K-271.48-111.26-25.93
P/B Ratio
31.0323.6370.4576.467.17
PTB ratio
31.0323.6370.4576.467.17
EV to sales
6.8312.935.428.944.52
Enterprise value over EBITDA
107.39145.27-361.2-55.53-20.36
EV to operating cash flow
95.79676.82-273.68-111.51-33.89
EV to free cash flow
101.361.61K-269.13-110.54-26.16
Earnings yield
000-0.01-0.08
Free cash flow yield
0.0100-0.01-0.04
Debt to equity
10.240.070.332.08
Debt to assets
0.380.180.060.220.43
Net debt to EBITDA
-0.1-2.843.150.36-0.18
Current ratio
1.77.310.954.720.98
Interest coverage
-1.5210.63-60.59-224.34-8.2
Income quality
30.25-0.50.870.480.39
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.610.590.440.890.62
Research and developement to revenue
0.250.090.040.140.1
Intangibles to total assets
0.330.13000.12
Capex to operating cash flow
-0.05-0.580.020.010.3
Capex to revenue
0-0.0100-0.04
Capex to depreciation
0-0.87-0.37-0.16-2.3
Stock based compensation to revenue
00.040.110.040.03
Graham number
0.071.042.92.31.02
ROIC
-0.940.14-0.19-0.65-0.89
Return on tangible assets
0.01-0.08-0.26-0.71-1.32
Graham Net
-0.030.350.890.23-0.19
Working capital
605.71K3.28M8.38M3.45M-53.67K
Tangible asset value
118.7K3.41M8.68M3.77M-107.98K
Net current asset value
83.16K2.37M8.11M2.38M-1.27M
Invested capital
10.240.070.332.08
Average receivables
376.55K612.84K1.34M1.44M853.97K
Average payables
253.31K367.58K295.72K366.93K603.09K
Average inventory
91.03K68.36K657.26K657.02K87.93K
Days sales outstanding
41.3138.8840.3536.1323.24
Days payables outstanding
325.5747.618.2133.8544.38
Days of inventory on hand
658.0840.223.997.28
Receivables turnover
8.849.399.0510.115.7
Payables turnover
1.127.6744.4510.788.22
Inventory turnover
5.6245.29.0891.3950.15
ROE
0.01-0.1-0.3-1.09-5.65
Capex per share
0-0.0100-0.05

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.290.30.223.30.87
Net income per share
-0.06-0.21-0.01-2.9-1.49
Operating cash flow per share
-0.070.15-0.090.48-0.26
Free cash flow per share
-0.080.13-0.10.41-0.26
Cash per share
0.040.130.121.090.01
Book value per share
0.170.090.07-1.94.89
Tangible book value per share
0.03-0.010.01-2.77-1.28
Share holders equity per share
0.170.090.07-1.94.89
Interest debt per share
0.210.210.111.722.85
Market cap
139.83M51.26M44.57M8.89M16.61M
Enterprise value
141.14M51.71M44.41M9.13M23.06M
P/E ratio
-69.5-7.25-178.58-1.13-1.18
Price to sales ratio
58.2620.2719.833.958.07
POCF ratio
-242.3741.67-47.8427.06-27.55
PFCF ratio
-221.0245.97-43.7632.12-27.55
P/B Ratio
99.9567.1768.03-6.871.44
PTB ratio
99.9567.1768.03-6.871.44
EV to sales
58.820.4519.764.0611.21
Enterprise value over EBITDA
-354.05-212.41-152.68-31.26-37.4
EV to operating cash flow
-244.6442.04-47.6827.79-38.24
EV to free cash flow
-223.0946.37-43.633-38.24
Earnings yield
0-0.030-0.22-0.21
Free cash flow yield
00.02-0.020.03-0.04
Debt to equity
1.162.081.58-0.760.56
Debt to assets
0.350.430.260.260.3
Net debt to EBITDA
-3.28-1.850.54-0.83-10.46
Current ratio
1.150.980.940.490.61
Interest coverage
-3.13-1.42-5.57-1.91-3.36
Income quality
1.09-0.941.37-0.17-0.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.630.590.740.691.04
Research and developement to revenue
0.120.130.10.20.2
Intangibles to total assets
0.230.120.130.160.67
Capex to operating cash flow
0.1-0.090.09-0.160
Capex to revenue
-0.02-0.05-0.04-0.020
Capex to depreciation
-0.86-5.27-1.66-0.970
Stock based compensation to revenue
0.01-0.020.030.010.3
Graham number
0.480.650.111.1312.81
ROIC
-0.09-0.11-0.02-0.55-0.97
Return on tangible assets
-0.14-0.54-0.02-0.63-0.5
Graham Net
-0.2-0.19-0.16-5.3-2.91
Working capital
311.65K-53.67K-164.04K-2.17M-3.54M
Tangible asset value
257.58K-107.98K117.22K-1.88M-3.02M
Net current asset value
-959.68K-1.27M-996.52K-2.94M-4.55M
Invested capital
1.162.081.58-0.760.56
Average receivables
1.37M1.23M718.44K753.68K1.52M
Average payables
969.8K736.78K622.46K689.67K1.1M
Average inventory
101.54K97.77K122.92K143.76K1.59M
Days sales outstanding
64.725.9428.3431.9697.99
Days payables outstanding
67.1166.5367.21128.18338.31
Days of inventory on hand
6.8510.9116.4523.94770.75
Receivables turnover
1.393.473.182.820.92
Payables turnover
1.341.351.340.70.27
Inventory turnover
13.148.255.473.760.12
ROE
-0.36-2.32-0.11.53-0.3
Capex per share
-0.01-0.01-0.01-0.080

MEDS Frequently Asked Questions

What is TRxADE HEALTH, Inc. stock symbol ?

TRxADE HEALTH, Inc. is a US stock , located in Land o'lakes of Fl and trading under the symbol MEDS

What is TRxADE HEALTH, Inc. stock quote today ?

TRxADE HEALTH, Inc. stock price is $10.17 today.

Is TRxADE HEALTH, Inc. stock public?

Yes, TRxADE HEALTH, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap